Patients and Methods of the PATH Biobank - A Resource for Breast Cancer Research.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Development of a patient advocate committee for a pediatric biobank.Research involvement and engagement · 2026
   Article
2. Basic principles of biobanking: from biological samples to precision medicine for patients.Virchows Archiv : an international journal of pathology · 2021
   Review
3. Differential regulation of AMP-activated protein kinase in healthy and cancer cells explains why V-ATPase inhibition selectively kills cancer cells.The Journal of biological chemistry · 2019
   Article
4. Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy.BMC cancer · 2019
   Observational
5. Robustness of biomarker determination in breast cancer by RT-qPCR: impact of tumor cell content, DCIS and non-neoplastic breast tissue.Diagnostic pathology · 2018
   Article
6. The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ERα-negative breast cancer.Oncogene · 2017
   Article
7. AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection.BMC cancer · 2016
   Article
8. Opportunities and Challenges for Drug Development: Public-Private Partnerships, Adaptive Designs and Big Data.Frontiers in pharmacology · 2016
   Review
9. The Treatment of Primary Breast Cancer in Older Women With Adjuvant Therapy: A Retrospective Analysis of Data From Over 3000 Patients From the PATH Biobank, With Two-Year Follow-up.Deutsches Arzteblatt international · 2015
   Article
10. Biobanking from the patient perspective.Research involvement and engagement · 2015
    Article
11. AGR3 in breast cancer: prognostic impact and suitable serum-based biomarker for early cancer detection.PloS one · 2015
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as